or Try an Advanced Search...

    ETF Components for FMED - Fidelity Disruptive Medicine ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    BSX B 0.38 6.63
    UNH D -0.38 4.26
    DHR D -0.31 3.86
    ISRG A 2.06 3.67
    CNC D -0.58 3.48
    PODD C 0.09 3.24
    ALNY A 0.94 3.23
    SYK B 1.58 2.66
    REGN B 0.99 2.64

    Represented by ETF Holdings

    Keywords: S&P 500 Medicine Medical Equipment Biopharmaceutical Biotechnology Bone Cholesterol Claims Processing Clinical Development Disease Durable Medical Equipment Endoscopy Formulary Health Management Managed Care Medicaid Medical Technology Nasdaq 100 Surgical Equipment Telehealth
    Industries: Medical Devices Biotechnology Health Care Plans Diagnostics & Research Medical Instruments & Supplies

    Recent News for Fidelity Disruptive Medicine ETF & its Holdings

    Date Stock Title
    Jul 5 REGN Swing Trading Regeneron Stock Shows How To Bob And Weave
    Jul 5 PODD (PODD) - Analyzing Insulet's Short Interest
    Jul 5 ALNY Baillie Gifford's Strategic Reduction in Alnylam Pharmaceuticals Holdings
    Jul 5 SYK Three Reasons to Hold BD (BDX) Stock in Your Portfolio Now
    Jul 5 CNC Health Net Providing Special Assistance to Members Affected by Thompson Fire in Butte County
    Jul 5 REGN Dupixent “addresses current gap” in COPD biologics landscape
    Jul 5 ISRG Jim Cramer Says You Should ‘Buy, Buy, Buy’ Intuitive Surgical Inc (NASDAQ:ISRG)
    Jul 5 UNH Why the Walmart Model Doesn’t Work in Healthcare
    Jul 4 ALNY An Intrinsic Calculation For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Suggests It's 50% Undervalued
    Jul 3 SYK Merit Medical (MMSI) Inks Deal to Boost Endoscopy Portfolio
    Jul 3 UNH The Dow Is Dipping. Blame UnitedHealth Stock.
    Jul 3 BSX Artisan Global Discovery Fund Trimmed Boston Scientific Corporation (BSX) for Valuation Discipline
    Jul 3 UNH Unpacking the Latest Options Trading Trends in UnitedHealth Group
    Jul 3 REGN Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
    Jul 3 REGN Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
    Jul 3 SYK Should You Investigate Stryker Corporation (NYSE:SYK) At US$334?
    Jul 3 REGN Sanofi, Regeneron win EU label expansion for Dupixent in COPD
    Jul 3 REGN Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
    Jul 2 REGN Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
    Jul 2 BSX Medtronic Loses 5% in a Month: What's Next for MDT Investors?
    The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.
    Back to the Main FMED Page...